


May 21, 2020

Online Symposium of the Korean Endocrine Society

Diagnosis and treatment of central diabetes insipidus

*Department of Endocrinology and Diabetes,
Nagoya University Graduate School of Medicine*

Hiroshi Arima

- 
- 
- Water balance
 - Diagnosis of central diabetes insipidus (CDI)
 - Treatment of CDI
 - Adipsic CDI
 - Familial neurohypophysial diabetes insipidus



- Water balance

- Diagnosis of central diabetes insipidus (CDI)


- Treatment of CDI

- Adipsic CDI


- Familial neurohypophysial diabetes insipidus

Synthesis and release of arginine vasopressin (AVP)


AVP neurons in hypothalamus



AVP is released in response to increases in serum Na



AVP is synthesized in response to increases in serum Na



Pituitary MRI



Pituitary AVP content is decreased under dehydration

Plasma AVP (pg/ml)	
Base	Dehydrated
1.65 ± 0.04	12.88 ± 2.43^c

AVP content ($\mu\text{g}/\text{pituitary}$)	
Base	Dehydrated
1.67 ± 0.10	0.59 ± 0.11^c

Pituitary AVP content is decreased under dehydration

Plasma AVP (pg/ml)	
Base	Dehydrated
1.65 ± 0.04	12.88 ± 2.43 ^c

AVP content (μg/pituitary)	
Base	Dehydrated
1.67 ± 0.10	0.59 ± 0.11 ^c

Pituitary AVP content is decreased under dehydration

Plasma AVP (pg/ml)	
Base	Dehydrated
1.65 ± 0.04	12.88 ± 2.43^c

AVP content ($\mu\text{g}/\text{pituitary}$)	
Base	Dehydrated
1.67 ± 0.10	0.59 ± 0.11^c




Serum Na

140 mEq/l


Water intake

Plasma AVP


Urine output




The half-life of AVP in plasma




AVP release and water intake




AVP release and water intake




AVP release and water intake




Threshold: Na 140 mEq/L

- 
- 
- Water balance
 - **Diagnosis of central diabetes insipidus (CDI)**
 - Treatment of CDI
 - Adipsic CDI
 - Familial neurohypophysial diabetes insipidus

AVP release and water intake



AVP release and water intake



threshold: Na 145 mEq/L

Pituitary MRI




Healthy control



CDI

Etiology of central diabetes insipidus





thirst

thirst


thirst

Serum Na

145 mEq/l

Plasma AVP

Urine output



Research on hypothalamic pituitary disorder

Ministry of Health, Labor, and Welfare

Mice deficient for ERAD ma 2017 JCI.pdf 2019年4月30日 巨人 vs 中E 間脳下垂体機能障害に関する調査研究

https://kannoukasuitai.jp/index.html

お気に入りをここに表示するには、★を選択し、次に☆を選択して、お気に入りバーのフォルダーにドラッグします。または、別のブラウザからインポートします。お気に入りのインポート

厚生労働科学研究費補助金難治性疾患等政策研究事業（難治性疾患政策研究事業）

間脳下垂体機能障害に関する調査研究

サイト内検索

- トップページ
- ごあいさつ
- 間脳下垂体とは
- 代表的な疾患
- メンバーおよび所属施設
- リンク

疾患の早期発見と
よりよい治療をめざして

お知らせ

2018.11.27 更新	2019年1月27日（日）	市民公開講座を開催します。
2018.02.13 更新	2018年2月10日（土）	市民公開講座が開催されました。

15:35 2019/04/30

Guidelines for diagnosis and treatment of hypothalamic pituitary disorders

published in 2019 (in Japanese)

1. Acromegaly
2. Cushing disease
3. Prolactinoma
4. Diabetes insipidus
5. SIADH
6. Congenital nephrogenic diabetes insipidus
7. Gonadotropin producing pituitary tumor
8. Central precocious puberty

Guidelines for diagnosis and treatment of hypothalamic pituitary disorders

published in 2019 (in Japanese)

9. TSH producing pituitary tumor
10. GH deficiency short stature
11. Transition from child to adult in GH deficiency
12. Adult GH deficiency
13. ACTH deficiency
14. Prolactin deficiency
15. Gonadotropin deficiency
16. TSH deficiency
17. Incidental pituitary tumor
18. Autoimmune hypophysitis
19. IgG4 related hypophysitis

Diagnosis of central diabetes insipidus

I . Main symptoms

1. thirst
2. polydipsia
3. polyuria

II. Inspection findings

1. Daily Urine volumes $>3,000$ ml or >40 ml/kg in adult
 $>2,000$ ml/m² in child
2. Urine osmolality < 300 mOsm/kg
3. Increases in AVP release during hypertonic saline injection are attenuated

Diagnosis of central diabetes insipidus

I . Main symptoms

1. thirst
2. polydipsia
3. polyuria

II. Inspection findings

1. Daily Urine volumes $>3,000$ ml or >40 ml/kg in adult
 $>2,000$ ml/m² in child
2. Urine osmolality < 300 mOsm/kg
3. Increases in AVP release during hypertonic saline injection are attenuated

Questions which should be asked before hypertonic saline injection test

- How much volume of water do you drink every day?
(how many PET bottles?)
- How often do you go to the bathroom at night?
(Don't you drink water or alcohol before going to bed?)
- Do you drink water when you wake up at night?
(Do you feel thirsty at night?)

AVP RIA in Japan

	AVP RIA 「Mitsubishi」	AVP RIA Neo 「SML」	AVP kit 「YAMASA」
Period	Until March, 2012	From June 2012 to February, 2017	Since march 2015
sensitivity	0.2 pg/mL	0.8 pg/mL	0.4 pg/mL
Cross- reactivity with DDAVP	0.1%	0.88%	< 0.001%

Control

Case	Gender	age	disease	Urine volumes		Urine osmolality	evaluation
				(mL/day)	(mL/kg/day)	(mOsm/kg)	
1	F	38	Craniopharingioma	638	11.3	468	Before TSS
2	F	26	normal	1,300	30.7	496	-
3	M	45	acromegaly	1,400	20.2	607	After TSS
4	F	76	acromegaly	2,150	35.6	484	After TSS
5	M	63	acromegaly	1,850	21.0	498	After TSS
6	F	63	normal	1,800	44.1	311	-
7	F	72	acromegaly	1,145	24.2	419	Before TSS
8	F	57	AGHD	2,110	36.1	575	After TSS
9	M	53	acromegaly	1,655	19.9	950	-
10	M	49	acromegaly	1,300	14.9	639	After TSS
11	M	71	acromegaly	1,250	20.4	618	After TSS
12	F	75	normal	1,500	25.0	290*	-
13	M	65	acromegaly	1,780	18.1	531	After TSS


CDI patients

Case	gender	age	After diagnosis	Urine volume		Urine osmolality	etiology
				(mL/day)	(mL/kg/day)	(mOsm/kg)	
1	M	42	0	9,000	124.0	111	idiopathic
2	M	46	0	5,600	87.6	103	idiopathic
3	F	62	0	8,060	155.0	n.d.	angiogranuloma
4	M	53	1	5,000	47.5	n.d.	Pituitary tumor
5	F	40	0	4,000	89.1	n.d.	Pituitary tumor
6	F	38	4	8,400	166.7	n.d.	craniopharyngioma
7	M	56	3	n.d.	n.d.	134	Pituitary tumor
8	F	32	0	5,600	107.7	126	Pituitary tumor
9	M	47	2	2,800	41.1	n.d.	IgG4
10	F	45	9	10,000	108.0	n.d.	idiopathic
11	F	53	0	3,500	53.0	159	Pituitary tumor
12	M	64	27	n.d.	n.d.	n.d.	idiopathic
13	M	73	0	2,740	52.7	n.d.	IgG4

AVP release during hypertonic saline injection


control

Plasma AVP (pg/mL)




CDI

Plasma AVP (pg/mL)




AVP release during hypertonic saline injection



There are no differences in basal values of plasma AVP between control and CDI


AVP release during hypertonic saline injection




① gradient of regression lines

② estimated plasma AVP values at serum Na 149 mEq/L


Gradient of regression lines




Gradient of regression lines



Gradient of regression lines





Gradient of regression lines





Diagnosis of CDI

using gradients of regression line




Gradient 0.1 → sensitivity 100% specificity 77%

Diagnosis of central diabetes insipidus using estimated plasma AVP concentrations at serum Na 149 mEq/L



Mean concentrations of serum Na after hypertonic saline injection were 149 mEq/L in control

Diagnosis of central diabetes insipidus using estimated plasma AVP concentrations at serum Na 149 mEq/L



Estimated plasma AVP 1.0 pg/ml at serum Na 149 mEq/L

→ sensitivity 99% specificity 95%

Research on hypothalamic pituitary disorder

Ministry of Health, Labor, and Welfare

Mice deficient for ERAD ma 2017 JCI.pdf 2019年4月30日 巨人 vs 中E 間脳下垂体機能障害に関する調査研究

https://kannoukasuitai.jp/index.html

お気に入りをここに表示するには、★を選択し、次に☆を選択して、お気に入りバーのフォルダーにドラッグします。または、別のブラウザからインポートします。お気に入りのインポート

厚生労働科学研究費補助金難治性疾患等政策研究事業（難治性疾患政策研究事業）

間脳下垂体機能障害に関する調査研究

サイト内検索

- トップページ
- ごあいさつ
- 間脳下垂体とは
- 代表的な疾患
- メンバーおよび所属施設
- リンク

疾患の早期発見と
よりよい治療をめざして

お知らせ

2018.11.27 更新	2019年1月27日（日）	市民公開講座を開催します。
2018.02.13 更新	2018年2月10日（土）	市民公開講座が開催されました。

15:35 2019/04/30


A tool to diagnose CDI

高張食塩水負荷試験 結果解析

	0	30	60	90	120
血清Na濃度 (mEq/L)	140	143	146	147	148
血漿AVP濃度 (pg/mL)	1.5	1.4	2.2	2.8	3.4

上の表に実際の測定値を入力して下さい。

0.4 pg/mL未満の場合は0.4を入力して下さい。



近似直線の傾き

血清Na149mEq/L時点の推定AVP値

中枢性尿崩症診断基準

< 0.1

(感度 100%, 特異度 77%)

< 1.0 pg/mL

(感度 99%, 特異度 95%)


A tool to diagnose CDI

高張食塩水負荷試験 結果解析

	0	30	60	90	120
血清Na濃度 (mEq/L)	140	143	146	147	148
血漿AVP濃度 (pg/mL)	1.5	1.4	2.2	2.8	3.4

上の表に実際の測定値を入力して下さい。

0.4 pg/mL未満の場合は0.4を入力して下さい。



近似直線の傾き

血清Na149mEq/L時点の推定AVP値

中枢性尿崩症診断基準

< 0.1

(感度 100%, 特異度 77%)

< 1.0 pg/mL

(感度 99%, 特異度 95%)


A tool to diagnose CDI

高張食塩水負荷試験 結果解析

	0	30	60	90	120
血清Na濃度 (mEq/L)	140	143	146	147	148
血漿AVP濃度 (pg/mL)	1.5	1.4	2.2	2.8	3.4

上の表に実際の測定値を入力して下さい。

0.4 pg/mL未満の場合は0.4を入力して下さい。



近似直線の傾き

0.233

血清Na149mEq/L時点の推定AVP値

3.237

中枢性尿崩症診断基準

< 0.1

(感度 100%, 特異度 77%)

< 1.0 pg/mL

(感度 99%, 特異度 95%)

Diagnosis of central diabetes insipidus

4. Urine osmolality does not exceed 300 mOsm/kg after **water is deprived for 6.5 h** or BW decreases by 3%.
5. Urine volumes decrease and urine osmolality increases above 300 mOsm/kg after 5 IU vasopressin sc injection after water deprivation.

Case 1: 75 years old female


Main symptoms

pollakisuria at night



Current medical history

She visited the urology department for pollakisuria. Then, she was introduced to the Endocrinology department to rule out diabetes insipidus.

Case 1: 75 years old female




Diagnosis of central diabetes insipidus using gradients of regression line




Gradient 0.1 → sensitivity 100% specificity 77%

Case 1: 75 years old female

Water deprivation test



CDI is unlikely



➤ Water balance

➤ Diagnosis of central diabetes insipidus (CDI)

➤ **Treatment of CDI**



➤ Adipsic CDI

➤ Familial neurohypophysial diabetes insipidus





Desmopressin formulation

デスモプレシンOD錠			デスモプレシン経鼻薬	
OD錠 60μg	OD錠 120μg	OD錠 240μg	スプレー2.5	点鼻液0.01%
				

Desmopressin・spray




Desmopressin・nasal solution




Hyponatremia in CDI patients treated with DDAVP (spray or nasal solution)

< 135 mEq/l




< 130 mEq/l




During 5 years


Hyponatremia in CDI patients treated with DDAVP (spray or nasal solution)



DDAVP formula and hyponatremia




Nasal DDAVP




Oral DDAVP

□ < 130 mEq/l □ 130-134 mEq/l □ 135-149 mEq/l □ 150-154 mEq/l


Relationship between plasma AVP and urine osmolality



Relationship between DDAVP and urine osmolality





Plasma DDAVP concentration after nasal injection




Serum Na

140 mEq/l




Plasma DDAVP

desmopressin



Urine volumes






Serum Na

140 mEq/l


Water intake

Plasma AVP

Urine output



Relationship between doses of DDAVP and antidiuretic effects




Case 2: 70 years old female treated with DDAVP

day	5/9	5/13	5/14	5/15
time		9:30	18:00	6:00
Serum Na	120	121	117	128



Δ Na : 11 mEq/L/12 h

Serum Na concentrations should be lowered when they rise more than expected




Case 2: 70 years old female treated with DDAVP


time	8:00	10:00	12:00	14:00	16:00	18:00
Urine volume	448	421	109	186	892	504
Serum Na	128		129			131
5% glucose						
DDAVP	60 μ g					60 μ g

Case 2: 70 years old female treated with DDAVP


time	8:00	10:00	12:00	14:00	16:00	18:00
Urine volume	448	421	109	186	892	504
Serum Na	128		129			131
5% glucose						
DDAVP	60 μ g					60 μ g

Changes in plasma DDAVP concentrations




- 
- 
- Water balance
 - Diagnosis of central diabetes insipidus (CDI)
 - Treatment of CDI
 - **Adipsic CDI**
 - Familial neurohypophysial diabetes insipidus


AVP release and water intake



AVP release and water intake




Case 3: 15 years old boy diagnosed CDI due to germ cell tumor




CDI patients with/without adipsia

		Non-adipsia	adipsia
Number of patients		126	23
Age of onset	<65 years	89%	91%
	<65years	11%	9%
gender	M	56%	52%
	F	44%	48%
hypopituitarism	(-)	37%	13%
	(+)	63%	87%

Serum Na concentrations




non-adipsia




adipsia

Hospitalization due to injection



non-adipsia




adipsia

Characteristics of patients who died during follow-up

patient	Adipsic/ non- adipsic	Age of CDI onset	etiology	Age of death	Cause of death
1	adipsic	25	inflammation	37	Sudden death
2	adipsic	12	malformation	42	pneumonia
3	adipsic	10	Germ cell tumor	51	cholecystitis
4	adipsic	77	inflammation	78	sepsis
5	Non- adipsic	21	Empty sella	49	influenza
6	Non- adipsic	66	Rathoke's cleft cyst	78	Renal failure


Kaplan-Meier Curves for OS of patients with or without adipsia



Treatment of adipsic patients

- The ideal BW for water balance should be determined based on serum Na concentrations (e.g. 60 kg)
- The basal water intake should be determined (e.g. 1L/day)
- The dose of DDAVP are determined so that daily urine volumes are around basal water intake (e.g. 1L/day)
- $\text{Daily water intake} = \text{Basal water intake} + (\text{ideal BW} - \text{BW})$


However, it is not practical to advise adipsic patients to take a high volume of water (e.g., 3L/day). So, just advise to take more water than 1L/day when the BW is decreased.

- 
- 
- Water balance
 - Diagnosis of central diabetes insipidus (CDI)
 - Treatment of CDI
 - Adipsic CDI
 - Familial neurohypophysial diabetes insipidus


Familial neurohypophysial diabetes insipidus (FNDI)

- Autosomal dominant disease.
- Polyuria appears several months or years after birth.
- Mutations exist mainly in the region of NPII rather than AVP gene.
- Mutant AVP precursors are accumulated in the ER of AVP neurons.
- Autopsy studies show AVP neuronal loss in patients with FNDI.

Mutations causing FNDI




Pedigree of FNDI patients with Cys98 Stop




patients	age	onset	urine (l/day)
A1	49	4	10
A2	19	4	10


Knock-in mice expressing Cys98stop




Expression of mutant NPII



WT mice




FNDI mice




Antibody for mutant NPII

Expression of normal NPII



WT mice




FNDI mice





Antibodies for normal NPII



Changes in urine volumes




Changes in numbers of AVP neurons




Analysis with electron microscopy



Mutant NP11




Normal NP11



AVP



Aggregates are confined to a compartment of ER lumen of AVP neurons in FNDI mice



ERAC


(Endoplasmic Reticulum-
Associated Compartment)

ERAC is connected to the rest of ER




ERAC: ER-associated compartment

The formation of ERAC is also reported in other diseases in which ER stress has been implicated in the pathophysiology.




Huyer G et al. 2004 **Mol Biol Cell**




Granell S et al., 2008 **Mol Biol Cell**

4-PBA reduces the number of ERAC



control



4-PBA 28days




Scale bar, 50 μ m




Tochiya et al., 2018 **Neurosci Lett**



4-PBA reduced urine volumes in FNDI mice





4-PBA reduced urine volumes in FNDI mice



AVP neurons are finally lost by mechanism of autophagy-associated cell death



AVP neurons differentiated from human ES cells



Nagoya University Graduate School of Medicine



Thank you for your attention